Ann Lurie, as president of Lurie Investment Fund (the venture capital arm of the Ann and Robert H. See sector focus and contact routes.
Ann Lurie, as president of Lurie Investment Fund (the venture capital arm of the Ann and Robert H. Lurie Foundation), invests primarily in early-stage and growth-oriented biomedical companies, focusing on medical devices, therapeutics, diagnostics, nanotechnology, and MEMS technology[1][2][3]. The firm’s investment range spans $2.5 million to $88 million, with notable portfolio companies including Viamet Pharmaceuticals ($60M Series D), NanoInk ($88M Series E), CytoPherx, HandyLab, and Aperion Biologics[2][4][15]. Lurie’s distinctive thesis centers on “social investing”—deploying venture capital into early-stage biomedical innovations that positively impact human health, particularly in molecular diagnostics and life-saving treatments[12].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Chicago when building a target list.
Investors like Ann Lurie · Full investor directory · Investor access · Company funding database